49
Participants
Start Date
June 14, 2019
Primary Completion Date
November 10, 2023
Study Completion Date
December 31, 2025
OPTIMOX-bevacizumab
"Induction Adapted FOLFOX7 (aFOLFOX7)-bevacizumab for 6 cycles (3 months)~* Bevacizumab: 5 mg/kg IV (day 1, every 2 weeks \[q2w\]),~* Folinic acid (FA): 400 mg/m² IV/2h (day 1, q2w),~* Oxaliplatin: 85 mg/m² IV/2h (day 1, q2w),~* 5-fluorouracil (5-FU) continuous infusion 2400 mg/m² IV/46h (day 1-2, q2w),~* No 5-FU bolus.~then Maintenance Adapted LV5FU2 (aLV5FU2)-bevacizumab (until progression or or unacceptable limiting toxicity)~* Bevacizumab: 5 mg/kg IV (day 1, q2w),~* FA: 400 mg/m² IV/2h (day 1, q2w),~* 5-FU continuous infusion 2400 mg/m² IV/46h (day 1-2, q2w)~* No 5-FU bolus"
Capecitabine plus bevacizumab
"* Bevacizumab: 7.5 mg/kg intravenous infusion \[IV\] (day 1; q3w),~* Capecitabine: 1000 mg/m² orally twice a day (day 1 through day 14, q3w)."
CH Abbeville, Abbeville
CHU Amiens Hôpital sud, Amiens
Clinique de l'Europe, Amiens
CH Beauvais, Beauvais
Hôpital Duchenne, Boulogne-sur-Mer
Centre hospitalier de Cannes, Cannes
CH Compiègne Noyon, Compiègne
UCOG Picardie Groupe Hospitalier, Creil
CHU Henri Mondor, Créteil
Centre geroges François Leclerc, Dijon
Institut Daniel Hollard, Grenoble
Institut Hospitalier Franco-Britannique, Levallois-Perret
Hôpital Privé Jean Mermoz, Lyon
Institut Paoli-Calmettes, Marseille
CH Sud Ile de France, Melun
CH Mont de Marsan, Mont-de-Marsan
Centre Antoine Lacassagne, Nice
Hôpital des Diaconnesses Croix Saint Simon, Paris
Hôpital Saint Antoine, Paris
Institut Mutualiste Montsouris, Paris
CH Annecy Genevois, Pringy
CH Saint Malo, St-Malo
GERCOR - Multidisciplinary Oncology Cooperative Group
OTHER